Analysis of urinary nucleosides as potential cancer markers determined using LC-MS technique

Journal of Pharmaceutical and Biomedical Analysis

Volumn 101, Issue , 2014, Pages 50-57

  Struck Lewicka, Wiktoria ^a   Kaliszan, Roman ^a   Markuszewski, Michał Jan ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Biomarkers; High performance liquid chromatography; Mass spectrometry detection; Metabolomics; Urinary nucleosides

Indexed keywords

NUCLEOSIDE DERIVATIVE; RNA; TUMOR MARKER; NUCLEOSIDE;

ANALYTIC METHOD; ANALYZER; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METABOLOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; URINE LEVEL; NEOPLASMS; PROCEDURES; URINE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MASS SPECTROMETRY; NEOPLASMS; NUCLEOSIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84908594019     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.04.022     Document Type: Review

References (71)

1. Kaur P., Sheikh K., Kirilyuk A., et al. Metabolomic profiling for biomarker discovery in pancreatic cancer. Int. J. Mass Spectrom. 2012, 310:44-51.
2. Schanckenberg L.K., Beger R.D. Metabolomic biomarkers: their role in the critical path. Drug Discov. Today: Technol. 2007, 4:13-16.
3. Kim Y.S., Maruvada P., Milner J.A. Metabolomics in biomarker discovery: future uses for cancer prevention. Future Oncol. 2008, 4:93-102.
4. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4:551-561.
5. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 2009, 15:431-440.
6. Ganti S., Weiss R.H. Urine metabolomics for kidney cancer detection and biomarker discovery. Metabolomics 2011, 29:551-557.
7. Woo H.M., Kim K.M., Choi M.H., et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin. Chim. Acta 2009, 400:63-69.
8. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 2007, 26:51-78.
9. Roux A., Lison D., Junot C., et al. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: a review. Clin. Biochem. 2011, 44(1):119-135.
10. Ceglarek U., Leichtle A., Brügel M., et al. Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mol. Cell. Endocrinol. 2009, 301:266-271.
11. Xiao J.F., Zhou B., Ressom H.W. Metabolite identification and quantitation in LC-MS/MS based metabolomics. Trends Anal. Chem. 2012, 32:1-14.
12. Lindon J.C., Nicholson J.K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. 2008, 1:45-49.
13. Madsen R., Lundstedt T., Trygg J. Chemometrics in metabolomics - a review in human disease diagnosis. Anal. Chim. Acta 2010, 659:23-33.
14. Blekherman G., Laubenbacher R., Cortes D.F., et al. Bioinformatics tools for cancer metabolomics. Metabolomics 2011, 7:329-343.
15. Limbach P.A., Crain P.F., McCloskey J.A. Summary the modified nucleosides of RNA. Nucleic Acids Res. 1994, 22:2183-2196.
16. Schram K.H. Urinary nucleosides. Mass Spectrom. Rev. 1998, 17:131-251.
17. Liebich H.M., Müller-Hagedorn S., Bacher M., et al. Age-dependence of urinary normal and modified nucleosides in childhood as determined by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 2005, 814:275-283.
18. Hsu W.Y., Chen W.T.L., Lin W.D., et al. Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clin. Chim. Acta 2009, 402:31-37.
19. Zheng Y.F., Yang J., Zhao X.J., et al. Urinary nucleosides as biological markers for patients with colorectal cancer. World J. Gastroenterol. 2005, 11:3871-3876.
20. Feng B., Zheng M.H., Zheng Y.F., et al. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. J. Gastroenterol. Hepatol. 2005, 20:1913-1919.
21. Hsu W.Y., Lin W.D., Tsai Y., et al. Analysis of urinary nucleosides as potential tumor markers in human breast cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clin. Chim. Acta 2011, 412:1861-1866.
22. Bullinger D., Fröhlich H., Klaus F., et al. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Anal. Chim. Acta 2008, 618:29-34.
23. Zheng Y.F., Kong H.W., Xiong J.H., et al. Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin. Biochem. 2005, 38:24-30.
24. Sasco A.J., Rey F., Reynaud C., et al. Breast cancer prognostic significance of some modified urinary nucleosides. Cancer Lett. 1996, 108:157-162.
25. Frickenschmidt A., Fröhlich H., Bullinger D., et al. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008, 13:435-449.
26. Cho S.H., Choi M.H., Lee W.Y., et al. Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal. Clin. Biochem. 2009, 42:540-543.
27. Mao Y., Zhao X., Wang S., et al. Urinary nucleosides based potential biomarker selection by support vector machine for bladder cancer recognition. Anal. Chim. Acta 2007, 598:34-40.
28. Kvist E., Sjølin K.E., Iversen J., et al. Urinary excretion patterns of pseudouridine and β-aminoisobutyric acid in patients with tumours of the urinary bladder. Scand. J. Urol. Nephrol. 1993, 27:45-53.
29. Szymańska E., Markuszewski M.J., Markuszewski M., et al. Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. J. Pharm. Biomed. Anal. 2010, 53:1305-1312.
30. Rasmuson T., Björk G.R. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncol. 1995, 34:61-67.
31. Itoh K., Konno T., Sasaki T., et al. Relationship of urinary pseudouridine and l-methyladenosine to activity of leukemia and lymphoma. Clin. Chim. Acta 1992, 206:181-189.
32. La S., Cho J.H., Kim J.H., et al. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Anal. Chim. Acta 2003, 486:171-182.
33. Kim K.R., La S., Kim A., et al. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from uterine myoma and cervical cancer patients. J. Chromatogr. B 2001, 754:97-106.
34. Reynaud C., Bruno C., Boullanger P., et al. Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies. Cancer Lett. 1992, 61:255-262.
35. Markuszewski M.J., Struck W., Waszczuk-Jankowska M., et al. Metabolomic approach for determination of urinary nucleosides as potential tumor markers using electromigration techniques. Electrophoresis 2010, 31:2300-2310.
36. Struck W., Waszczuk-Jankowska M., Kaliszan R., et al. The state-of-the-art determination of urinary nucleosides using chromatographic techniques "hyphenated" with advanced bioinformatic methods. Anal. Bioanal. Chem. 2011, 401:2039-2050.
37. Fernández-Peralbo M.A., Luque de Castro M.D. Preparation of urine samples prior to targeted or untargeted metabolomics mass-spectrometry analysis. Trends Anal. Chem. 2012, 41:75-85.
38. Spaine D.M., Mamizuka E.M., Cedenho A.P., et al. Microbiologic aerobic studies on normal male urethra. Urology 2000, 56:207-210.
39. Kośliński P., Jarzemski P., Markuszewski M.J., et al. Determination of pterins in urine by HPLC with UV and fluorescent detection using different types of chromatographic stationary phases (HILIC, RP C8, RP C18). J. Pharm. Biomed. Anal. 2014, 91:37-45.
40. Rodriguez-Gonzalo E., Garcia-Gómez D., Carabias-Martinez R. Development and validation of a hydrophilic interaction chromatography-tandem mass spectrometry method with on-line polar extraction for the analysis of urinary nucleosides. Potential application in clinical diagnosis. J. Chromatogr. A 2011, 1218:9055-9069.
41. Kammerer B., Frickenschmidt A., Müller C.E., et al. Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling. Anal. Bioanal. Chem. 2005, 382:1017-1026.
42. Takeda N., Yoshizumi H., Niwa T. Detection and characterization of modified nucleosides in serum and urine of uremic patients using capillary liquid chromatography-frit-fast atom bombardment mass spectrometry. J. Chromatogr. B 2000, 746:51-62.
43. Liebich H.M., Müller-Hagedorn S., Klaus F., et al. Chromatographic, capillary electrophoretic and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of urinary modified nucleosides as tumor markers. J. Chromatogr. A 2005, 1071:271-275.
44. Kammerer B., Frickenschmidt A., Gleiter C.H. MALDI-TOF MS analysis of urinary nucleosides. J. Am. Soc. Mass Spectrom. 2005, 16:940-947.
45. Bullinger D., Fux R., Nicholson G., et al. Identification of urinary modified nucleosides and ribosylated metabolites in human via combined ESI-FTICR MS and ESI-IT MS analysis. J. Am. Soc. Mass Spectrom. 2008, 19:1500-1513.
46. Henneges C., Bullinger D., Fux R., et al. Prediction of breast cancer by profiling of urinary RNA metabolites using support vector machine-based feature selection. BMC Cancer 2009, 9:104-114.
47. Zhao X., Wang W., Wang J., et al. Urinary profiling investigation of metabolites with cis-diol structure from cancer patients based on UPLC-MS and HPLC-MS as well as multivariate statistical analysis. J. Sep. Sci. 2006, 29:2444-2451.
48. Dudley E., Lemiere F., Dongen W.V., et al. Analysis of urinary nucleosides. III. Identification of 5'-deoxycytidine in urine of a patient with head and neck cancer. Rapid Commun. Mass Spectrom. 2003, 17:1132-1136.
49. Jeng L.B., Lo W.Y., Hsu W.Y., et al. Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis. Rapid Commun. Mass Spectrom. 2009, 23:1543-1549.
50. Teichert F., Winkler S., Keun H.C., et al. Evaluation of urinary ribonucleoside profiling for clinical biomarker discovery using constant neutral loss scanning liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2011, 25:2071-2082.
51. Tuytten R., Lemière F., Esmans E.L., et al. Role of nitrogen Lewis basicity in boronate affinity chromatography of nucleosides. Anal. Chem. 2007, 79:6662-6669.
52. Li H.Y., Wang S.M., Liu H.M., et al. Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/electrospray tandem mass spectrometry. J. Mass Spectrom. 2009, 44:641-651.
53. Rodriguez-Gonzalo E., Hernández-Prieto R., Garcia-Gomez D., et al. Development of a procedure for the isolation and enrichment of modified nucleosides and nucleobases from urine prior to their determination by capillary electrophoresis-mass spectrometry. J. Pharm. Biomed. Anal. 2014, 88:489-496.
54. Tuytten R., Lemière F., Van Dongen W., et al. Development of an on-line SPE-LC-ESI-MS method for urinary nucleosides: hyphenation of aprotic boronic acid chromatography with hydrophilic interaction LC-ESI-MS. Anal. Chem. 2008, 80:1263-1271.
55. Lee S.H., Jung B.H., Kim S.Y., et al. A rapid and sensitive method for quantification of nucleosides in human urine using liquid chromatography/mass spectrometry with direct urine injection. Rapid Commun. Mass Spectrom. 2004, 18:973-977.
56. Rodriguez-Gonzalo E., Hernández-Prieto R., Garcia-Gomez D., et al. Capillary electrophoresis-mass spectrometry for direct determination of urinary modified nucleosides. Evaluation of synthetic urine as a surrogate matrix for quantitative analysis. J. Chromatogr. B 2013, 942:21-30.
57. Waszczuk-Jankowska M., Markuszewski M.J., Markuszewski M., et al. Comparison of RP-HPLC columns used for determination of nucleoside metabolic patterns in urine of cancer patients. Bioanalysis 2012, 4:1185-1194.
58. Da Pieve C., Sahgal N., Moore S.A., et al. Development of a liquid chromatography/tandem mass spectrometry method to investigate the presence of biomarkers of DNA damage in urine related to red meat consumption and risk of colorectal cancer. Rapid Commun. Mass Spectrom. 2013, 27:2493-2503.
59. Hsu W.Y., Chen C.J., Huang Y.C., et al. Urinary nucleosides as biomarkers of breast, colon, lung, and gastric cancer in Taiwanese. PLoS ONE 2013, 8(12):e81701.
60. Garcia-Gomez D., Rodriguez-Gonzalo E., Carabias-Martinez R. Stationary phases for separation of nucleosides and nucleotides by hydrophilic interaction liquid chromatography. Trends Anal. Chem. 2013, 47:111-128.
61. Kloos D.P., Lingeman H., Niessen W.M.A., et al. Evaluation of different column chemistries for fast urinary metabolic profiling. J. Chromatogr. B 2013, 927:90-96.
62. Dudley E., El-Sharkawi S., Games D.E., et al. Analysis of urinary nucleosides, I. Optimisation of high performance liquid chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14:1200-1207.
63. Dudley E., Tuytten R., Alison B., et al. Study of the mass spectrometric fragmentation of pseudouridine: comparison of fragmentation data obtained by matrix-assisted laser desorption/ionisation post-source decay, electrospray ion trap multistage mass spectrometry, and by a method utilising electrospray quadrupole time-of-flight tandem mass spectrometry and in-source fragmentation. Rapid Commun. Mass Spectrom. 2005, 19:3075-3085.
64. Sarracino D., Richert C., et al. Quantitative MALDI-TOF MS of oligonucleotides and a nuclease assay. Bioorg. Med. Chem. Lett. 1996, 6:2543-2548.
65. Duncan M.W., Roder H., Hunsucker S.W. Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Brief Funct. Genomics Proteom. 2008, 7:355-370.
66. Dudley E., Lemiére F., Van Dongen W., et al. Analysis of urinary nucleosides, II. Comparison of mass spectrometric methods for the analysis of urinary nucleosides. Rapid Commun. Mass Spectrom. 2001, 15:1701-1707.
67. Dudley E., Lemiére F., Van Dongen W., et al. Analysis of urinary nucleosides, IV. Identification of urinary purine nucleosides by liquid chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2004, 18:2730-2738.
68. Bond A., Dudley E., Lemiére F., et al. Analysis of urinary nucleosides, V. Identification of urinary pyrimidine nucleosides by liquid chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:137-150.
69. Struck W., Siluk D., Yumba-Mpanga A., et al. Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers. J. Chromatogr. A 2013, 1283:122-131.
70. Zamora-Ros R., Montserrat R., Cherubini A., et al. Comparison of 24-h volume and creatinine-corrected total urinary polyphenol as a biomarker of total dietary polyphenols in the invecchiare in CHIANTI study. Anal. Chim. Acta 2011, 704:110-115.
71. Warrack B.M., Hnatyshyn S., Ott K.H., et al. Normalization strategies for metabonomic analysis of urine samples. J. Chromatogr. B 2009, 877:547-552.